Targeting Tumor Microvasculature of Malignant Metastatic Tumor

Topic Information

Dear Colleagues,

The formation of the blood supply system is an important step in the cancerous transformation of cells, resulting in the penetration of tumor cells into the neighboring tissues and metastatic growth. Significant progress in the elucidation of mechanisms underlying tumor angiogenesis, along with the discovery of a great diversity of biomolecules involved in its regulation, have culminated in the development of a radically novel approach to antitumor therapy based on the search for effective inhibitors of tumor angiogenesis. Angiogenesis inhibitors target the neovascular development that is hypothesized as triggering tumor growth. The inhibitors that are involved in the search for the anti-angiogenesis process can be divided into five categories, based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block angiogenesis activators; 4) drugs that inhibit endothelial cell integrins or survival signaling; and 5) drugs with a currently unknown mechanism of action. In recent years, a great deal of research has been focused on the search for novel anti angiogenic drugs in the area of endogenous peptides, small organic molecules, microRNAs, cytotoxic molecules and so on. In this vein, we welcome original research, cutting-edge reviews and clinical trials. These should related, but not limited, to the aspects of the field listed: identification of small molecules, endogenous peptides, small organic molecules, microRNAs, cytotoxic molecules, antibody-drug conjugates, synergistic combination therapy, synthetic and natural biomolecules, nanoparticles and repurposing drugs, etc., against regulation of tumor angiogenesis and metastasis towards the identification of new anti-angiogenic drugs.

Dr. Prabhu Thirusangu
Dr. Vigneshwaran Vellingiri
Dr. Prabhakar Thippegowda
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Cancers cancers	4.5	8.0	2009	17.4 Days	CHF 2900
Current Oncology curroncol	2.8	3.3	1994	19.8 Days	CHF 2200
Journal of Clinical Medicine jcm	3.0	5.7	2012	16 Days	CHF 2600
Journal of Personalized Medicine jpm	-	4.1	2011	17.4 Days	CHF 2600
Onco onco	-	-	2021	27.8 Days	CHF 1000

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers